Xianzhe Li

- Participated in projects involving foreign medical technology companies exiting the Chinese market by selling their Chinese operations. Drafted project proposals for mergers and acquisitions. - Through research and analysis of the company's business situation, the existing medical technology sector, and past exit cases of foreign medical technology companies, assisted the company in preparing executive summaries and information memoranda. Assisted in screening potential buyers.

- Independently completed an investment value analysis report for Dingtai Pharmaceutical Research. - Completed an in-depth research report on Dongyangguang Pharmaceutical and corresponding financial modeling. Post successful report defense, the report was shared with multiple partner firms for reference. - Completed research on WuXi AppTec and the U.S. Biosafety Act. - Participated in a company interview with Dingtai Pharmaceutica, together with investment banking teams of Citigroup and Guotai Haitong.

- Collaborated with the lead industry analyst to conduct industry research on stablecoins, supply chain finance, and cross- border payments. Conducted special research on the stablecoin bill implemented in Hong Kong. - Independently completed in-depth reports on Circle and Lianyirong, which focused on the role of accounts receivable securitization linked to blockchain and the stablecoin bill in promoting internet finance. - Responsible for compiling comments on the semi-annual reports of all companies under the team's supervision and for corresponding financial modeling.

- Participated in and supported the listing of Nali New Materials and Han's Robot on the Hong Kong Stock Exchange, and played a key role in drafting the prospectus and listing project proposal. - Responded to the Stock Exchange's inquiries based on the circumstances of the companies assisting with their listing. - Participated in expert interviews and documented meeting minutes.

- Responsible for the innovative drug sub-segment within the group's broader healthcare sector. Assisted mentors in writing strategy reports for the innovative drug development sector and monitored policy updates and technological advancements in the sector. - Continuously monitored the operating conditions of our portfolio companies, and evaluated the effectiveness of the investments by combining their periodic reports with industry conditions.

First class honor Dean‘s list